Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas

PurposeTo assess amide proton transfer-weighted (APTW) imaging features in patients with malignant gliomas after chemoradiation and the diagnostic performance of APT imaging for distinguishing true progression from pseudoprogression. Materials and MethodsAfter approval by the Institutional Review Board, 32 patients with clinically suspected tumor progression in the first 3 months after chemoradiation were enrolled and scanned at 3T. Longitudinal routine magnetic resonance imaging (MRI) changes and medical records were assessed to confirm true progression versus pseudoprogression. True progression was defined as lesions progressing on serial imaging over 6 months, and pseudoprogression was defined as lesions stabilizing or regressing without intervention. The APTW(mean) and APTW(max) signals were obtained from three to five regions of interests for each patient and compared between the true progression and pseudoprogression groups. The diagnostic performance was assessed with receiver operating characteristic curve analysis. ResultsThe true progression was associated with APTW hyperintensity (APTW(mean)=2.75%0.42%), while pseudoprogression was associated with APTW isointensity to mild hyperintensity (APTW(mean)=1.56%+/- 0.42%). The APTW signal intensities were significantly higher in the true progression group (n=20) than in the pseudoprogression group (P < 0.001; n=12). The cutoff APTW(mean) and APTW(max) intensity values to distinguish between true progression and pseudoprogression were 2.42% (with a sensitivity of 85.0% and a specificity of 100%) and 2.54% (with a sensitivity of 95.0% and a specificity of 91.7%), respectively. ConclusionThe APTW-MRI signal is a valuable imaging biomarker for distinguishing pseudoprogression from true progression in glioma patients. J. Magn. Reson. Imaging 2016;44:456-462.